Two weeks worth of news articles linked here:
Actos: safer than Avandia?
Cialis going toward a once-daily version (but shouldn’t it be once every day-and-a-half??)
Novartis gets some approvals in Europe, including new diabetes treatment Galvus
Wyeth’s Pristiq gets stalled by FDA (Pristiq is a cousin of Effexor)
GPC setback on cancer treatment
Medpointe being bought by a Swedish firm
AZ slashing jobs (mostly overseas)
Some earnings reports: BMS, Celgene, Mylan, Shire
Pfizer entering the patent black hole: Losing Lipitor
Schering’s reliance on cholesterol pills
Motley Fool asks – Amylin: Two hit wonder?
Next up on the Whistleblower Express: Novartis
Purdue hammered again with fines for Oxycontin marketing
And, a long-ish article in Pharmaceutical Executive magazine entitled Fixing the Sales Model.
Plus: Medical Marketing and Media’s annual lollapalooza of Agencies and Brands. Some good info and downloads here.